Earnings call transcript: WELL Health Q4 2025 shows strong EPS beat

WELL Health reported Q4 EPS of CAD 0.20 versus a CAD 0.1035 forecast (a 93.24% beat) while Q4 revenue narrowly missed at CAD 384.77m vs CAD 385.23m (-0.12%), and the stock fell ~2.38% pre-market to CAD 4.11. Full-year 2025: revenue CAD 1.4bn (+52% YoY), adjusted EBITDA CAD 203.7m (margin 14.5% vs 5.1% in 2024), adjusted net income CAD 126.5m (CAD 0.50/sh), and free cash flow CAD 58.2m (+19%). Management reiterated FY2026 guidance (revenue CAD 1.55–1.65bn; adjusted EBITDA CAD 175–185m), highlighted WELLSTAR/HEALWELL AI growth and a CAD ~260m Canadian clinic M&A pipeline, expanded a Canadian credit facility to CAD 400m and continues US divestiture processes (Circle Medical DOJ provision updated to CAD 3.3m); key risks include sustaining revenue growth, regulatory/Litigation noise and M&A integration.

Analysis

WELL’s print magnified a two-speed business: a clinic-driven cash flow engine that benefits disproportionately from workflow automation and a nascent software/AI layer that scales with low incremental cost. The market hasn’t fully separated recurring, normalized EBITDA from accounting noise (deferred revenue recognition and cyber-related adjustments), which creates a near-term valuation disconnect that can reverse quickly on clear divestiture or spin-out news.

Strategically, WELL’s combination of owned clinic distribution and validated AI creates a unique data flywheel that pharma sponsors and large health systems will pay for — patient-consent pools and trial-recruitment capabilities are asymmetric value drivers versus standalone SaaS. Provincial licensure and diagnostic licensing act as durable barriers-to-entry, inflating acquisition multiples for buyers and increasing strategic optionality for WELL (retain-and-monetize vs sell-and-return-capital).

Key risks are binary and timing-sensitive: final DOJ/California resolution, successful divestiture of U.S. assets, and a WELLSTAR spin/IPO are the primary catalysts; failure or delay on any increases downside via multiple compression. Operational risks (M&A integration, provincial regulatory hurdles) play out over quarters to years, while accounting normalization events can swing sentiment in days to weeks — trade around catalyst windows, not headline EPS beats alone.

Key Decisions for Investors

• Long WELL.TO (scale-in): Establish a 3–5% portfolio position, add on any >10% pullback. Target a 50–100% upside over 6–18 months contingent on a WELLSTAR spin or U.S. asset sale; hard stop at -30% to protect against headline/settlement shocks.
• Pairs trade — Long HWAIF / Short CRH (equal notional): Size modestly (1–3% net exposure). Rationale: HEALWELL’s enterprise AI contracts should re-rate independently of U.S. delivery-noise that depresses CRH; expect positive spread capture over 6–12 months if divestiture processes progress.
• Options hedge (event-driven): Buy a 6–12 month WELL.TO call spread to retain upside while limiting cost (buy near-term ATM call, sell 2x OTM call). Use this into key catalysts (DOJ settlement, spin/asset sale) — target 2.5x–3x return if catalyst hits, max loss = premium paid.
• Liquidity play (short-term): Avoid being long into near-term headline windows absent a clear divestiture timeline. Use put protection or reduce position size in the 1–3 week window around announced settlement dates or M&A closing periods to guard against volatility.